Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies

LONDON, June 29, 2015 /PRNewswire/ --

Dermatological drugs - new study showing you trends, partnerships, and predicted revenues
Where is the market for dermatological drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 310 page report provides 220 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket, regional and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales:
• Kathleen Deardorff, Chief Operating Officer (COO) at Photocure ASA

You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:
• Skin infection drugs market forecast 2015-2025
• Dermatitis drugs market forecast 2015-2025
• Acne drugs market forecast 2015-2025
• Psoriasis drugs market forecast 2015-2025
• Other dermatological drugs market forecast 2015-2025

Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.

To see a report overview please email Sara Peerun on [email protected]

See revenue forecasts for products
How will leading drugs perform to 2025 at world level? Our study forecasts sales of 24 products, including these brands:
• Remicade
• Humira
• Claravis
• Epiduo
• Bepanthen
• Solodyn
• Enbrel
• Protopic
• Cubicin
• Canesten

Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?
Our analyses show sustained growth in the dermatological drugs market, particularly in the emerging economies where growing affluence and rising government support will impact the growth of dermatological drugs.

In addition to analyses of the overall world market, you discover individual revenue forecasts for national and regional markets to 2025. Future trends within each region are examined. You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.
• US
• China
• Japan
• Germany
• India
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• Mexico
• Rest of the World

To see a report overview please email Sara Peerun on [email protected]

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth
Over the last few years, the market for dermatological drugs globally has witnessed a number of strategic acquisitions and restructuring. The global dermatological drugs market will reach $24.5bn in 2015, according to visiongain's forecast. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs, and antibacterial drug resistance will aid in the growth of the overall market to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:
• AbbVie
• Galderma
• GlaxoSmithKline
• Johnson & Johnson
• LEO Pharma
• Pfizer

A company profile gives you the following information:
• Revenue forecast for dermatological drugs from 2015 to 2025
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
• Discussion of a company's activities and outlook

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?

Research and development activities - assess innovation, trends and possibilities
What is happening in the R&D pipeline for dermatological treatments? You see developmental trends, gaining insight into each phase of the dermatology R&D pipeline for:
• Acne pipeline drugs
• Dermatitis pipeline drugs
• Psoriasis pipeline drugs
• Skin infections pipeline drugs
• Other progress in dermatology

Our study also discusses these agents and technologies, among others:
• Photodynamic therapy
• Drug delivery
• Novel small molecules
• Oral drug candidates

What issues will affect the dermatological drugs market?
Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting dermatological treatments. You will find discussions, including qualitative analyses:
• Pricing and reimbursement pressures created by government cost-cutting initiatives
• Patient compliance and the advances in topical drug delivery
• A strong R&D pipeline
• Personalised dermatology and genomics
• Consolidation among players in the market
• Patent expiries and generic competition
• The changing socio-economic conditions impacting dermatological drug demand
• Demographic trends impacting demand for dermatological drugs

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape

How the Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies report helps you
In summary our 310 page report gives you the following knowledge:
• Revenues to 2025 for the overall dermatological drugs market - discover the industry's prospects, finding promising areas for investments and revenues
• Revenue forecasts to 2025 for four product categories (therapeutic classes) within dermatological drugs - discover forecasts for Psoriasis drugs, Dermatitis drugs, Acne drugs, Skin infection drugs, and Other dermatological drugs
• Revenue forecast to 2025 for 12 leading national markets - US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World
• Assess leading companies - hear about the products, results and strategies, including recent activities, future outlook, and dermatological drugs revenue forecast for 6 leading companies, including Pfizer, LEO Pharma, Johnson & Johnson, AbbVie, and GlaxoSmithKline
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities
• IP protection and generic drug competition - see what affects product revenue

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the dermatological drugs market and the leading companies within it. You will find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on [email protected]

Companies Mentioned in the Report

Abbott Laboratories
AbbVie
AbGenomics
Actavis
Actelion
AET BioTech
Affinium (DebioPharm Group)
AiCuris
Alembic Pharmaceuticals
Alkem Laboratories
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
AndroScience Group
AnGes M G
Anterios
Apeiron Biologics
Ascend Therapeutics
Astellas Pharma
Astion Pharma
AstraZeneca
Asubio Pharma (Daiichi Sankyo)
Atrix Laboratories
Aurobindo Pharma
Ausio Pharmaceuticals
Barr Laboratories
Basilea Pharmaceutica
Bayer
Boehringer Ingelheim
Berg Pharma
Bertek Pharmaceuticals
Biocon
Biofrontera
Biogen Idec
Biotest AG
Biovail Laboratories
BioXpress Therapeutics
Birken AG
Braintree Laboratories
Bristol-Myers Squibb
Cadila Healthcare
Can-Fite Biopharma
Cardinal Health
Celgene
Cellceutix
Celltech
Celltrion
Celsus Therapeutics
Cempra Inc
Cipher Pharmaceuticals
Cipla
Circassia
CollaGenex
Compañía Internacional de Comercio
Convoy Therapeutics
Cosmo Pharmaceuticals
Creabilis Therapeutics
Cubist Pharmaceuticals
Cutanea Life Sciences
DAVA Pharmaceuticals
Delenex Therapeutics
Dermira Inc
Dow Pharmaceutical Sciences
Dr Reddy's Laboratories
Durata Therapeutics
Eisai
Eli Lilly
Elorac
Foamix
Fortuderm
Forward Pharma
Fougera Pharmaceuticals (Sandoz)
Fujifilm
Fujisawa Healthcare
Furiex Pharmaceuticals
G&E Herbal Biotechnology
G&W Laboratories
Galderma (Nestle)
Gene Signal
Genentech (Roche)
Genpharm
Genzyme (Sanofi)
GlaxoSmithKline
Glenmark Pharmaceuticals
Grupo Imperial
Hanwha Pharma
Heritage Pharmaceuticals
Hospira
Idera Pharmaceuticals
Immune Response BioPharma Inc
Immunex
Impax Laboratories
Incyte
Innovaderm Research
Instituto Terapeutico Delta Ltda
Intrepid Therapeutics
Janssen Biotech
Johnson & Johnson
Kosei
Kyowa Hakko Kirin
L'Oreal
Laboratorios Kendrick
LEO Foundation
LEO Pharma
Lupin Pharmaceuticals
Maruho
Meda Pharma
Medicis (Valeant)
Medison Pharma
Melinta Pharmaceuticals
Merck & Co
Mitsubishi Tanabe Pharma
Moleculin
MorphoSys
Mycenax Biotech
Mylan
Nabriva Therapeutics
NanoBio Corporation
Nestle
NovaBay
Novartis
OpthaliX
Par Pharmaceutical
Paratek Pharmaceuticals
Peplin (LEO Pharma)
Perrigo
Pfizer
Pharmacia (Pfizer)
PharmaPraxis
Photocure
Pierre Fabre
Pliva Hrvatska
Precision Dermatology
Provectus Biopharmaceuticals
Q-Med
Ranbaxy
Regeneron
Roche
Rochester Drug Co-operative
Roxane Laboratories
S.A.P.I. de C.V. (CISCA)
Samsung Bioepis
Sandoz (Novartis)
Sanofi
Shape Pharmaceuticals
Shionogi & Co
Sidmak Laboratories
Sol-Gel Technologies
Stiefel Laboratories (GSK)
Sun Pharmaceuticals
Sunovion Pharmaceuticals
Switch Biotech
Taisho Pharmaceuticals
Takeda
Targanta Therapeutics
Taro Pharmaceuticals
Tecnofarma
Telormedix
Teva
The Medicines Company
Therapeutics Inc
Theravance
Tolmar Inc
Topica Pharmaceuticals
Trius Therapeutics
UCB Pharma
Valeant Pharmaceuticals
Vatera Healthcare Partners
VBL Therapeutics
Vedara Therapeutics
ViiV Healthcare (GSK)
ViroBay
Vitacilina Corporation of America (VitaCorp)
Warner Chilcott (Actavis)
Welichem Biotech
Wolters Kluwer
Wyeth (Pfizer)
XBiotech
XenoPort
Xoma

Organisations Mentioned in the Report

Brazilian Society of Dermatology
British Association of Dermatologists
Chinese Society of Dermatology
European Medicines Agency (EMA)
European Pharmaceutical Market Research Association (EPhMRA)
Food and Drug Administration (FDA) [US]
Health Canada
National Development and Reform Commission (NDRC) [China]
National Health Services (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Allergy and Infectious Diseases (NIAID) [US]
National Institutes of Health [US]
National Pharmaceutical Pricing Authority (NPPA) [China]
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Servicio Sanitario Nazionale (SSN) [US]
St. Luke's-Roosevelt Hospital Center, New York [US]
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
United States District Court for the District of New Jersey
University of California, San Diego [US]
University of Michigan [US]
US Patent Office

To request an exec summary of this report please email Sara Peerun at [email protected]
or call Tel: +44(0)20-7336-6100
Or click on https://goo.gl/TqVun7

SOURCE Visiongain